Acute graft-versus-host disease—biologic process, prevention, and therapy
When T cells from a bone marrow donor begin to attack the host within 3 months after
hematopoietic-cell transplantation, acute graft-versus-host disease results. The disease
mainly affects the skin, liver, and gastrointestinal tract and is treated with
immunosuppressive drugs.
hematopoietic-cell transplantation, acute graft-versus-host disease results. The disease
mainly affects the skin, liver, and gastrointestinal tract and is treated with
immunosuppressive drugs.
[HTML][HTML] Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease
R Zeiser, N von Bubnoff, J Butler, M Mohty… - … England Journal of …, 2020 - Mass Medical Soc
Background Acute graft-versus-host disease (GVHD) remains a major limitation of
allogeneic stem-cell transplantation; not all patients have a response to standard
glucocorticoid treatment. In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and
JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory acute
GVHD. Methods We conducted a multicenter, randomized, open-label, phase 3 trial
comparing the efficacy and safety of oral ruxolitinib (10 mg twice daily) with the investigator's …
allogeneic stem-cell transplantation; not all patients have a response to standard
glucocorticoid treatment. In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and
JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory acute
GVHD. Methods We conducted a multicenter, randomized, open-label, phase 3 trial
comparing the efficacy and safety of oral ruxolitinib (10 mg twice daily) with the investigator's …
